LPL Financial
IMUC

LPL Financial’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

LPL Financial’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-275
Closed -$4K – 3270
2016
Q1 		$4K Hold
275
– – ﹤0.01% 3097
2015
Q4 		$4K Buy
+275
New +$4.54K ﹤0.01% 3153

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

LPL Financial's IMUC Position: Q2 2016 in Review

LPL Financial sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2016, closing a stake of 275 shares — an estimated $4K sold.

LPL Financial first reported a position in IMUC in Q4 2015 and held it in 2 quarters. The position peaked at $4K in Q1 2016. 36 funds tracked by Wall St. Rank hold IMUC as of Q2 2016.

  • LPL Financial reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2016 after selling out during the quarter.
  • LPL Financial sold 275 ImmunoCellular Therapeutics, Ltd. shares in Q2 2016, an estimated $4K.
  • LPL Financial first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2015 and held it in 2 quarters.
  • LPL Financial's ImmunoCellular Therapeutics, Ltd. position peaked at $4K in Q1 2016.
  • 36 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2016.

Based on LPL Financial's 13F filing for Q2 2016, filed 15 Aug 2016.